How do Aβ-PET scans perform in the "anti-amyloid" AD treatment era?

Tuesday, December 1 | 9:30 a.m.- 10:30 a.m. | T3-SSNR06-3 | Room E351

Beta-amyloid PET (Aβ-PET) shows promise for monitoring anti-amyloid Alzheimer's disease (AD) treatment, according to research to be shared Tuesday morning.

 The results shed light on the efficacy of an emerging treatment of Alzheimer's disease, namely the use of lecanemab and donanemab -- monoclonal antibody infusions that clear amyloid-beta protein from the brain, presenter Jazza Jamil, MBBS, of North West School of Medicine in Peshawar, Pakistan, and colleagues noted.

A recent trial assessed treatment intervals of 18 and six months for lecanemab and donanemab, respectively, but data regarding their use beyond these particular intervals are limited. To address the knowledge gap, Jamil's group conducted a study that included 12 patients with mild cognitive impairment due to AD being treated with lecanemab (n=4) or donanemab (n=8) who underwent baseline and at least two follow-up Aβ-PET scans. Mean time to the first follow-up Aβ-PET exam was 17.1 months for lecanemab patients and 10.7 months for donanemab patients.

The team noted the following:

· Mean change in centiloid imaging values overall was -71.92.

· Mean change in centiloid imaging values for lecanemab was -93.2 and for donanemab was -61.3 (p=0.21).

· Mean interval between the baseline Aβ-PET scan and the follow-up exam was seven months for lecanemab and six months for donanemab.

· Mild amyloid-related imaging abnormalities (ARIA) occurred in two patients receiving donanemab, with onset times of 4.1 and 5.1 months; one of these patients experienced a second episode of mild ARIA eight months later.

 The takeaway? "As the use of lecanemab and donanemab expands beyond trial-defined durations, this study provides real-world evidence to guide Aβ-PET-based monitoring during extended anti-amyloid therapy in Alzheimer disease," the investigators concluded.

Page 1 of 2
Next Page